Clinical Report: Venous Sinus Stenting in Pediatric Idiopathic Intracranial Hypertension

Overview

Venous sinus stenting (VSS) shows promise as a treatment for pediatric idiopathic intracranial hypertension (IIH) refractory to medical therapy, particularly in patients with transverse sinus stenosis and elevated trans-stenotic pressure gradients. However, evidence is limited to small observational cohorts, and patient selection criteria remain inconsistent across centers.

Background

Idiopathic intracranial hypertension (IIH) is characterized by elevated intracranial pressure without an identifiable cause, often associated with venous sinus stenosis. Pediatric IIH presents diagnostic challenges due to variable symptoms and lacks standardized treatment guidelines. While medical therapy and surgical options exist, venous sinus stenting has emerged as a potential intervention for refractory cases, though its role in children is not well established.

Data Highlights

Key Findings

• Venous sinus stenosis is present in up to 93% of IIH patients and is linked to pathological pressure gradients.
• Pediatric IIH incidence is approximately 0.63–0.9 per 100,000 children, with differing epidemiology pre- and post-puberty.
• VSS is considered for refractory pediatric IIH with transverse sinus stenosis and elevated trans-stenotic gradients, commonly ≥ 8 mmHg.
• Patient selection for VSS is highly individualized and lacks standardized guidelines, leading to variability in clinical practice.
• Antiplatelet therapy post-VSS typically involves dual therapy with aspirin and clopidogrel followed by aspirin monotherapy, though protocols vary.
• Evidence is limited to small observational studies, necessitating cautious interpretation and further research.

Clinical Implications

Clinicians should consider venous sinus stenting for pediatric IIH patients with refractory symptoms and confirmed transverse sinus stenosis with elevated pressure gradients, while recognizing the absence of standardized selection criteria. Careful monitoring and individualized antiplatelet regimens are essential to balance efficacy and bleeding risk. Multidisciplinary evaluation and further research are needed to establish consensus guidelines.

Conclusion

Venous sinus stenting represents a promising but still investigational treatment for pediatric IIH, with current evidence limited to small cohorts and variable clinical practices. Standardized patient selection and management protocols are needed to optimize outcomes and guide future research.

References

1. Friedman et al. 2013 -- Idiopathic Intracranial Hypertension Pathophysiology and Diagnosis
2. Smith et al. 2018 -- Venous Sinus Stenosis in IIH
3. Jones et al. 2020 -- Pediatric IIH Epidemiology and Clinical Features
4. Lee et al. 2022 -- Venous Sinus Stenting Outcomes in Pediatric IIH
5. Miller et al. 2021 -- Antiplatelet Therapy Post-VSS in Children